Dear Friends of Verseon,
Happy 2025!
As the new year begins, we've taken some time to reflect on 2024 and our vision for the year ahead.
New benchmark test results showed our proprietary AI technology VersAITM outshines Deep Learning AI in dynamic, rapidly changing environments that require fast predictive model generation.

VersAI trains models 3,000 times faster than current state-of-the-art Google AutoML

VersAI Training Speed
 
Forbes Magazine featured Verseon's platform as THE drug-discovery solution of the future.

Verseon has built a seamless platform... to design never-before-made novel drug molecules on the computer

Forbes Article
 
And Inside Precision Medicine covered how our technology enables exploration of unlimited possibilities to find novel drug candidates inaccessible to anyone else.

New tech unlocks seemingly infinite chemical space that could generate trillions of dollars per year

Inside Precision Medicine
 
Our new partner NeuTherX's scalable organoid technology will give us early insight into how patients will respond to our novel drug candidates before clinical trials begin, reducing the time and expense associated with drug development.

NeuTherX and Verseon partner to turbocharge preclinical drug development using scalable organoid testing

NeuTherX Partnership
 

Verseon's newly patented PROACs prevent heart attacks and strokes without the bleeding risks posed by other drugs

PROAC Patent Announcement
 
As Verseon continues to develop therapeutics no one else in the industry can, we hope to see significant ramp-up of the company's growth in 2025.
Wishing you a happy and prosperous New Year,
Adityo


Platform |  Pipeline |  About |  News |  Contact